Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2702
Abstract: Background: GQ1001 was developed to overcome the current limitation of existing HER2 ADCs by using the next generation site-specific conjugation and a stable linker technology, coined the intelligent ligase-dependent conjugation (iLDC) technology. iLDC provides a… read more here.
Keywords: gq1001; her2; her2 targeting; generation ... See more keywords
Abstract CT178: GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct178
Abstract: Background: GQ1001 is a novel HER2-targeted antibody-drug conjugate (ADC) that was developed using innovative conjugation technologies coined intelligent Ligase-Dependent Conjugation (iLDC), that can significantly improves homogeneity and biostability of ADC. In preclinical studies, GQ1001 showed… read more here.
Keywords: dose; gq1001; her2; phase study ... See more keywords
Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e13020
Abstract: e13020 Background: GQ1001 is a novel HER2-targeted antibody-drug conjugate (ADC) that was generated by conjugating trastuzumab to DM1 via a unique open-ring containing linker and the enzymatic site-specific conjugation technology, which significantly improves homogeneity and… read more here.
Keywords: gq1001; cancer; breast cancer; metastatic breast ... See more keywords